| Literature DB >> 33141760 |
Yi Xie1, Xiaohao Zhang1, Pengfei Xu2, Nana Zhao1, Ying Zhao1, Yunzi Li1, Ye Hong1, Mengna Peng1, Kang Yuan3, Ting Wan1, Rui Sun3, Deyan Chen4, Lili Xu5, Jingjing Chen3, Hongquan Guo6, Wanying Shan1, Juanji Li1, Rongrong Li1, Yunyun Xiong7,8, Dezhi Liu9, Yuhui Wang10, George Liu10, Ruidong Ye1, Xinfeng Liu1,2.
Abstract
Oligodendrocytes express low-density lipoprotein receptor (LDLR) to endocytose cholesterol for the maintenance of adulthood myelination. However, the potential role of LDLR in chronic cerebral ischemia-related demyelination remains unclear. We used bilateral carotid artery stenosis (BCAS) to induce sustained cerebral ischemia in mice. This hypoxic-ischemic injury caused a remarkable decrease in oligodendroglial LDLR, with impaired oligodendroglial differentiation and survival. Oligodendroglial cholesterol levels, however, remained unchanged. Mouse miR-344e-3p and the human homolog miR-410-3p, 2 miRNAs directly targeting Ldlr, were identified in experimental and clinical leukoaraiosis and were thus implicated in the LDLR reduction. Lentiviral delivery of LDLR ameliorated demyelination following chronic cerebral ischemia. By contrast, Ldlr-/- mice displayed inadequate myelination in the corpus callosum. Ldlr-/- oligodendrocyte progenitor cells (OPCs) exhibited reduced ability to differentiate and myelinate axons in vitro. Transplantation with Ldlr-/- OPCs could not rescue the BCAS-induced demyelination. Such LDLR-dependent myelin restoration might involve a physical interaction of the Asn-Pro-Val-Tyr (NPVY) motif with the phosphotyrosine binding domain of Shc, which subsequently activated the MEK/ERK pathway. Together, our findings demonstrate that the aberrant oligodendroglial LDLR in chronic cerebral ischemia impairs myelination through intracellular signal transduction. Preservation of oligodendroglial LDLR may provide a promising approach to treat ischemic demyelination.Entities:
Keywords: Cell Biology; Demyelinating disorders; Lipoproteins; Neuroscience; hypoxia
Year: 2021 PMID: 33141760 PMCID: PMC7773390 DOI: 10.1172/JCI128114
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808